drugset
drugset / Trial / NCT05300451

Daratumumab in HLA Desensitization Prior to Transplantation

NCT05300451 ↗

Phase 2 Enrolling by invitation 10 enrolled Barry A. Boilson Janssen Biotech, Inc. · collab
NaSingle-groupOpen-labelPrevention

Summary

The purpose of this study is to learn about how well the drug daratumumab/hyaluronidase-fihj (DARZALEX Faspro™) helps to lower high levels of HLA (Human Leukocyte Antigen) antibodies in a person waiting for a heart transplant.

Timeline

Start
2022-03-31
Primary completion
2026-08
Completion
2026-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Daratumumab and hyaluronidase-fihj Monoclonal antibody 1800 mg Subcutaneous
Subject Daratumumab and hyaluronidase-fihj Monoclonal antibody 30000 iu Subcutaneous

Indications

No indication recorded.